ip 9

WHI-P97 HCl 211555-05-4(free base) 是一种有效的选择性 JAK-3 抑制剂。 WHI-P97 在模型研究中估计 Ki 值为 0.09 microM，在 EGFR 激酶抑制试验中测得的 IC50 值为 2.5 microM。 WHI-P97以浓度依赖性方式有效抑制EGFR 阳性人癌细胞的体外侵袭性。

WHI-P97 是一种选择性 JAK-3抑制剂，可用于预防过敏性哮喘的研究。

ISOGINKGETIN (4',4'''-Dimethylamentoflavone) 是一种MMP9抑制剂，也是一种Pre-mRNA Splicing 抑制剂。

NBI-42902 is a potent inhibitor of peptide radioligand binding to the human GnRH receptor (K(i) = 0.56 nm). Tritiated NBI-42902 binds with high affinity (K(d) = 0.19 nm) to a single class of binding sites and can be displaced by a range of peptide and nonpeptide GnRH receptor ligands. In vitro experiments demonstrate that NBI-42902 is a potent functional, competitive antagonist of GnRH stimulated IP accumulation, Ca(2+) flux, and ERK1/2 activation. It did not stimulate histamine release from rat peritoneal mast cells. Finally, it is effective in lowering serum LH in castrated male macaques after oral administration. Overall, these data provide a benchmark of pharmacological characteristics required for a nonpeptide GnRH antagonist to effectively suppress gonadotropins in humans and suggest that NBI-42902 may have clinical utility as an oral agent for suppression of the hypothalamic-pituitary-gonadal axis. (source: Endocrinology. 2007 Feb;148(2):857-67. Epub 2006 Nov 9.)

DHFR-IN-9（化合物8A）是一种二氢叶酸还原酶（DHFR）抑制剂，通过干扰细胞内嘌呤和胸苷酸的生物合成而影响细胞生长和增殖。该化合物对抗耐甲氧西林金黄色葡萄球菌（MRSA）ATCC 43300展现出显著的抑制效果（IC50=0.25 μg/mL），并在全身及大腿感染的小鼠模型中显示出抗感染能力（剂量：2.5 mg/kg，5 mg/kg；ip）。此外，DHFR-IN-9在乳腺癌小鼠模型中展示了超过紫杉醇（Y-B0015）的抗癌活性（剂量：2.5 mg/kg；ip；每3天1次）。

SDH-IN-9 (compound Ip)作为Succinate Dehydrogenase的有效抑制剂，对Fusarium graminearum Schw展现出了0.93 μg/mL的EC50值。